<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Urine biomarkers for the detection of urothelial (transitional cell) carcinoma of the bladder</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Urine biomarkers for the detection of urothelial (transitional cell) carcinoma of the bladder</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Urine biomarkers for the detection of urothelial (transitional cell) carcinoma of the bladder</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anirban P Mitra, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc Birkhahn, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David F Penson, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Cote, MD, FRCPath</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Seth P Lerner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 18, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Urine biomarkers that are approved or under development for urothelial cancer are discussed in this topic. The clinical presentation and initial diagnosis of bladder cancer, the rationale and overall approach to screening high-risk populations, and the approach to surveillance in patients who have been treated for non-muscle invasive disease are discussed separately. (See  <a class="medical medical_review" href="/d/html/2989.html" rel="external">"Clinical presentation, diagnosis, and staging of bladder cancer"</a> and  <a class="medical medical_review" href="/d/html/2977.html" rel="external">"Screening for bladder cancer"</a> and  <a class="medical medical_review" href="/d/html/2996.html" rel="external">"Treatment of primary non-muscle invasive urothelial bladder cancer", section on 'Posttreatment surveillance'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">POTENTIAL APPLICATIONS</span><span class="headingEndMark"> — </span>Urine biomarkers have potential applications in individuals in whom bladder cancer is suspected based on the presence of hematuria, overactive bladder symptoms, or an unusually high risk of tumor. Urine biomarkers may also have a role in detecting recurrences in patients who have been treated for non-muscle invasive disease. They may also be used in the evaluation of upper tract radiographic abnormalities and for monitoring patients after treatment of ureteral or renal pelvic transitional cell carcinoma.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial diagnosis</strong> – The diagnosis of bladder cancer commonly is suggested by the presence of hematuria, which may be either gross or microscopic. However, hematuria is frequently seen in a wide range of benign conditions. The diagnosis of bladder cancer ultimately requires a histologic diagnosis, which usually comes from a biopsy that is obtained at cystoscopy. Cytology may provide strong evidence for the presence of malignancy, and a positive cytology should prompt further investigation. Urine biomarkers could have a significant role in determining which individuals require cystoscopy, as well as determining those who might need evaluation of the upper urinary tract. (See  <a class="medical medical_review" href="/d/html/2989.html" rel="external">"Clinical presentation, diagnosis, and staging of bladder cancer", section on 'Initial evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surveillance</strong> – Patients who have been treated for non-muscle invasive bladder cancer are at risk for recurrence in the bladder as well as for the development of urothelial tumors in the renal pelvis, ureter, or urethra. These patients, thus, require prolonged follow-up. (See  <a class="medical medical_review" href="/d/html/2996.html" rel="external">"Treatment of primary non-muscle invasive urothelial bladder cancer", section on 'Posttreatment surveillance'</a>.)</p><p></p><p class="bulletIndent1">Cystoscopy is the gold standard for surveillance in patients with a history of bladder cancer. Because it does not detect all recurrences nor does it visualize the upper urinary tract, a biomarker test should accompany cystoscopy in order to minimize the risk of missing a high-grade tumor. Furthermore, cystoscopy is a minimally invasive procedure. Cystoscopy is easily performed in an office setting with flexible instrumentation. However, it can be uncomfortable and promote anxiety, which can lead to suboptimal compliance with management recommendations. (See  <a class="medical medical_review" href="/d/html/2989.html" rel="external">"Clinical presentation, diagnosis, and staging of bladder cancer", section on 'Cystoscopy'</a>.)</p><p></p><p class="bulletIndent1">Cytology of voided urine or bladder washings is commonly used as an adjunct to cystoscopy, particularly to detect lesions that might be missed by cystoscopy. While bladder wash urine cytology has a high sensitivity for high-grade papillary tumors and carcinoma in situ, it has relatively low sensitivity for low-grade tumors. Cytology may be complemented with another voided urine biomarker with better performance characteristics for low-grade tumors as a supplement to or in lieu of cytology as long as the biomarkers have similar performance characteristics to cytology for high-grade tumors. (See  <a class="medical medical_review" href="/d/html/2989.html" rel="external">"Clinical presentation, diagnosis, and staging of bladder cancer", section on 'Urine cytology'</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">URINE BIOMARKERS</span><span class="headingEndMark"> — </span>Urine is exposed to the urothelium in the renal pelvis, ureters, bladder, and urethra, and thus, can contain a variety of molecular markers that may be associated with neoplasia. Urine also contains cells that have been shed. These cells provide the basis for cytology, as well as newer techniques for protein and cellular analysis. A number of markers and techniques have been evaluated. Many of these are based on immunologic detection of soluble molecules in the urine  (<a class="graphic graphic_table graphicRef70530" href="/d/graphic/70530.html" rel="external">table 1</a>). Other techniques analyze exfoliated cells that are isolated from urine or bladder washings by centrifugation  (<a class="graphic graphic_table graphicRef59814" href="/d/graphic/59814.html" rel="external">table 2</a>).</p><p>There have been modifications to cytologic specimen preparation for exfoliated cells, including liquid-based ThinPrep technology and urine microfiltration. These may potentially allow for improved cytomorphologic evaluation and assessment of cellular biomarkers [<a href="#rid1">1,2</a>].</p><p>An ideal test to detect early urothelial neoplasia should be inexpensive, rapid, and require little or no training and no specialized instrumentation. Such a test would be both highly sensitive and specific. False-negative results can lead to a missed diagnosis and disease progression while false-positive results cause unnecessary evaluations and associated patient anxiety. In some cases, a so-called false-positive test may actually be an anticipatory true-positive test, heralding the development of a visible tumor on subsequent evaluation.</p><p>The various approaches to develop urine biomarkers are discussed in this section. The relative performances of these tests have also been compared extensively in literature reviews [<a href="#rid3">3-5</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Bladder tumor antigen assays</span><span class="headingEndMark"> — </span>Assays have been developed to detect human complement factor H-related protein (hCFHrp) in the urine. This marker is similar in composition, structure, and function to human complement factor H (hCFH). Bladder tumor antigen (BTA)-stat is a qualitative point-of-care assay, the result of which can be interpreted within five minutes. BTA-TRAK is a specialized quantitative enzyme-linked immunosorbent assay (ELISA). The BTA assay may be particularly sensitive for detecting bladder cancer in patients with a history of schistosomiasis [<a href="#rid6">6</a>].</p><p>This technology was systematically evaluated by the FinnBladder Group in 501 patients with a history of bladder cancer [<a href="#rid7">7</a>]. Recurrent bladder cancer was detected by cystoscopy in 133 (27 percent). Pre-cystoscopy BTA assay was more sensitive than cytology (56 versus 19 percent) but less specific (86 versus 98 percent). In six cases in which the BTA assay was positive and cystoscopy was negative, bladder cancer was found at the next cystoscopy, and in three additional cases, upper urinary tract cancer was subsequently identified. Chou et al pointed out a higher sensitivity for evaluation of symptoms than for surveillance of tumor recurrence, while specificity was similar [<a href="#rid5">5</a>]. A meta-analysis of 13 studies consisting of 3462 patients with bladder cancer concluded that while BTA-stat has greater sensitivity than urine cytology, its specificity, likelihood ratios, and diagnostic odds ratios were relatively lower [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Nuclear matrix protein 22</span><span class="headingEndMark"> — </span>Nuclear matrix proteins (NMPs) serve as a scaffold in the nucleus and help regulate mitosis. Several of the NMPs are overexpressed in urothelial tumors and released into the urine following apoptosis of tumor cells. NMP22 has been the most extensively evaluated NMP, and assays for this antigen are used as an aid for bladder cancer diagnosis (in patients with hematuria) and can be used to monitor for cancer recurrence following treatment.</p><p>The NMP22 assay has lower sensitivity for Ta tumors (42 to 76 percent) compared with muscle-invasive tumors (50 to 98 percent) [<a href="#rid9">9</a>]. The NMP22 test may be more sensitive for schistosomal bladder cancers [<a href="#rid6">6,10</a>]. The potential role of this assay has been evaluated in several trials [<a href="#rid11">11-13</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>The NMP22 assay and cytology were compared in 1331 individuals at high risk for bladder cancer, all of whom underwent diagnostic cystoscopy [<a href="#rid11">11</a>]. Bladder cancer was diagnosed in 79 patients. The NMP22 assay detected 44 of these (56 percent), whereas cytology detected 12 (16 percent). While NMP22 had a lower specificity than cytology (86 versus 99 percent), it detected a bladder cancer in four cases that were missed on initial cystoscopy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The NMP22 assay, cytology, and cystoscopy were performed in a study of 668 consecutive patients undergoing surveillance for bladder cancer [<a href="#rid12">12</a>]. The NMP22 assay and cystoscopy detected 50 and 91 percent of the 103 recurrences, respectively. The NMP22 test detected eight of the nine cancers initially missed by cystoscopy, for a combined sensitivity of 99 percent. Cytology detected three of the nine cases initially missed at cystoscopy. The NMP22 assay had a specificity of 87 percent. In a study of 2222 patients with history of non-muscle invasive bladder cancer and negative urine cytology, NMP22 levels were significantly associated with disease recurrence and progression [<a href="#rid13">13</a>].</p><p></p><p>A prospective analysis of four commercially available urine marker tests and urine cytology for bladder cancer surveillance concluded that the combination of cytology and NMP22 seemed to increase the sensitivity for detecting high-grade tumors compared with single markers and other combinations [<a href="#rid14">14</a>]. The general use of the NMP22 assay for screening high-risk populations (smokers, high-risk occupations) rather than for surveillance is more problematic because of the low prevalence of urothelial neoplasia in these populations.</p><p class="headingAnchor" id="H6"><span class="h2">Other nuclear matrix proteins</span></p><p class="headingAnchor" id="H7"><span class="h3">NMP52</span><span class="headingEndMark"> — </span>NMP52 is a 52 kDa NMP similar to NMP22. A semiquantitative, rapid point-of-care assay has been developed to identify NMP52 in the urine of bladder cancer patients [<a href="#rid15">15</a>]. While performance metrics for the assay appear encouraging, there are sparse data, with most cases in the published series being limited to high-stage, high-grade tumors [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H8"><span class="h3">BLCA-4 and BLCA-1</span><span class="headingEndMark"> — </span>BLCA-4 and BLCA-1 are protein components of the nuclear matrix that are present exclusively in the urothelium of patients with bladder tumors and are absent in normal individuals [<a href="#rid16">16</a>]. BLCA-1 is expressed in bladder tumor but not adjacent normal tissues. In contrast, BLCA-4 is present throughout the bladder in both tumor and normal tissue in patients with bladder cancer [<a href="#rid17">17,18</a>]. Thus, BLCA-4 may reflect the field effect observed at the molecular level in normal tissues adjacent to tumors. Small studies have reported sensitivity and specificity of 80 to 96 and 87 to 100 percent, respectively, although larger prospective studies are required.</p><p class="headingAnchor" id="H282568260"><span class="h2">UroVysion</span><span class="headingEndMark"> — </span>Chromosomal alterations in bladder cancer can be detected by fluorescent in situ hybridization (FISH) assays, in which hybridization of fluorescently labeled DNA probes to chromosome centromeres or other loci on exfoliated cells is detected with a fluorescent microscope.</p><p>The UroVysion test is a multicolor FISH assay using probes that can detect aneuploidy of chromosomes 3, 7, or 17 or loss of the 9p21 locus. As marketed, the criteria for positivity are ≥4 of 25 morphologically abnormal cells showing a gain of ≥2 chromosomes in the same cell or ≥12 of the 25 cells having a loss of 9p21. If neither criterion is met, additional cells are analyzed until four cells with a gain of multiple chromosomes have been detected, 12 cells with loss of 9p21 are detected, or the entire sample has been analyzed.</p><p>The sensitivity of UroVysion for bladder cancer detection varies between 69 and 87 percent, and the specificity ranges from 89 to 96 percent [<a href="#rid19">19-21</a>]. Better performance has been reported in detecting carcinoma in situ and high-grade tumors [<a href="#rid22">22</a>]. In a prospective validation study on patients at risk for bladder cancer with atypical cytology, UroVysion was unnecessary when the tumor was obvious on cystoscopy [<a href="#rid23">23</a>]. However, it was useful in patients with atypical cytology and equivocal or negative cystoscopy. There are some data that UroVysion may be useful for monitoring patients with non-muscle invasive bladder cancer for response to intravesical therapy [<a href="#rid24">24-26</a>]. For example, patients with a positive test result at the end of treatment appear to be at higher risk for recurrence and progression to muscle-invasive disease.</p><p>UroVysion detects some occult tumors that are not visible on cystoscopy in the urine of patients under surveillance. Chromosomal abnormalities in exfoliated cells have preceded bladder tumors identifiable by cystoscopy within one year in 41 to 89 percent of patients [<a href="#rid27">27-30</a>]. The test is US Food and Drug Administration (FDA)-approved for use as an aid for initial diagnosis of bladder cancer in subjects with hematuria and for subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer.</p><p class="headingAnchor" id="H9"><span class="h2">Cytokeratins</span><span class="headingEndMark"> — </span>Cytokeratins (CKs) are crucial protein components of the epithelial cellular cytoskeleton. Epithelium can be characterized by its chain-specific CK expression pattern, and overexpression of certain CKs is associated with bladder cancer.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CK 8 and 18</strong> – Two commercial, antibody-based, solid-phase sandwich assays measure CK 8 and 18 in the urine (UBC ELISA and UBC IRMA). Detection sensitivity is lower for low-stage and low-grade bladder tumors [<a href="#rid31">31</a>]. The specificity is lower in individuals where urinary tract infection is present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CK 19</strong> – CYFRA21-1 is an ELISA that measures soluble fragments of CK 19 in the urine. A standardized cut-off is unavailable, and studies usually employ normalization to urine creatinine [<a href="#rid31">31</a>]. Detection sensitivity for low-stage and low-grade bladder tumors could be as low as 25 percent and 13 percent, respectively [<a href="#rid31">31</a>]. The specificity is lower in individuals where urinary tract infection is present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CK 20</strong> – Reverse transcription-polymerase chain reaction (RT-PCR) and immunocytochemistry have been employed to measure CK 20 levels, although additional studies are required to characterize their utility.</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Hyaluronic acid and hyaluronidase</span><span class="headingEndMark"> — </span>Hyaluronic acid (HA) is a nonsulfated glycosaminoglycan that regulates cell adhesion, migration, and proliferation and promotes tumor progression and metastasis. HA is cleaved by hyaluronidase (HAase) into small fragments that promote tumor angiogenesis.</p><p>Urinary levels of HA and HAase are measured by ELISA-like assays [<a href="#rid32">32</a>]. Both protein levels are normalized to total urinary protein.</p><p>In a study of 513 individuals (261 urothelial carcinoma patients, 9 non-urothelial bladder tumors, and 243 controls), the HA and HAase tests had sensitivities of 83 percent and 82 percent, respectively, and specificities of 90 and 84 percent, respectively [<a href="#rid32">32</a>]. However, the high sensitivity of HAase was only observed for grade II and III bladder cancers. The combination of these tests resulted in an overall sensitivity and specificity of 92 and 84 percent, respectively. The sensitivities of the combined test to detect non-muscle invasive and muscle-invasive tumors were 87 to 94 percent and 93 to 100 percent, respectively, while those for grade I, II, and III tumors were 86, 96, and 93 percent, respectively. Another independent study showed that the urinary HA test had an overall sensitivity of 82 percent and an overall specificity of 81 percent [<a href="#rid33">33</a>]. Analysis of the cohort also indicated that every 1 mcg/L increase in HA increased a patient's likelihood of having bladder cancer by 3.9 percent.</p><p>These results are promising, especially because of the apparent ability to detect low-grade and low-stage disease with higher sensitivity than most other markers. Additional validation studies are required to confirm these observations.</p><p class="headingAnchor" id="H11"><span class="h2">Telomerase</span><span class="headingEndMark"> — </span>Telomeres are repeated DNA sequences that cap the 5' ends of eukaryotic chromosomes and prevent the loss of crucial genetic information at the end of each DNA replication cycle. Loss of telomeres leads to chromosomal instability and cellular senescence.</p><p>Telomerase is a ribonuclease protein complex that adds telomeres to the 5' ends of chromosomes, thereby allowing cells to replicate indefinitely. Telomerase is expressed in germ cells, proliferating cells such as leukocytes, and tumor cells; normal somatic cells do not express telomerase. The presence of telomerase in the urine is a sensitive marker for urologic neoplasms.</p><p>The telomeric repeat amplification protocol (TRAP) is a specialized assay that detects the presence of telomerase in exfoliated cells [<a href="#rid34">34</a>]. A related assay measures the messenger RNA levels of human telomerase reverse transcriptase (hTERT), the catalytic subunit of telomerase, by RT-PCR. hTERT itself has been shown to be significantly associated with risk of tumor recurrence [<a href="#rid35">35</a>].</p><p>Both assays are significantly affected by sample collection and processing, which limits their clinical application. Degradation of telomerase and hTERT by urine can decrease assay sensitivity dramatically.</p><p class="headingAnchor" id="H12"><span class="h2">Survivin</span><span class="headingEndMark"> — </span>Survivin is an inhibitor of apoptosis. Survivin is elevated in human cancers but is almost undetectable in normal human tissues [<a href="#rid36">36</a>]. However, assays for survivin are not commercially available.</p><p>Survivin has been detected in urine using an antibody-based biodot test and a quantitative RT-PCR assay. Initial studies on this marker offer promising results, although further studies with larger patient cohorts are needed [<a href="#rid37">37-42</a>]. Meta-analyses suggest that survivin tests may have better sensitivity but lower specificity than urine cytology for detecting bladder tumors [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Fibrin degradation products</span><span class="headingEndMark"> — </span>High levels of vascular endothelial growth factor (VEGF) in bladder cancer cells increase the permeability of the surrounding vasculature, which results in leakage of serum proteins, including plasminogen, fibrinogen, and clotting factors. Clotting factors convert plasminogen to plasmin and fibrinogen to fibrin. Plasmin can further degrade fibrin to fibrin degradation products [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Microsatellite analysis</span><span class="headingEndMark"> — </span>Microsatellites are highly polymorphic repeating units of one to six nucleotides. The number of repeats at any chromosomal locus is different in each individual and even between the maternal and paternal alleles in the same somatic cell.</p><p>Observed microsatellite alterations in exfoliated bladder tumor cells detected by PCR include loss of heterozygosity (74 percent), length alterations (24 percent), and additional alleles (2 percent) [<a href="#rid45">45</a>]. Assessment of microsatellite alterations has been suggested as a potential alternative to cystoscopy for non-muscle invasive bladder cancer surveillance, although concerns regarding sensitivity and cost-effectiveness remain [<a href="#rid46">46-48</a>].</p><p>While modestly sensitive and specific for bladder cancer, loss of heterozygosity and microsatellite alterations are also seen in cystitis and benign prostatic hyperplasia, and this is more pronounced when these benign conditions are present concurrently [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Immunocytology</span><span class="headingEndMark"> — </span>Immunofluorescence technology has been used to detect cellular markers of bladder cancer in exfoliated cells from voided urine. One method of immunocytology is the ImmunoCyt assay (also marketed as uCyt+), which uses three fluorescently labeled monoclonal antibodies to detect carcinoembryonic antigen and two mucin glycoproteins that are expressed on most bladder cancer cells but not on normal cells.</p><p>The test requires urine fixation with ethanol or isopropyl alcohol before shipment to a reference cytopathology laboratory. A minimum evaluation of 500 epithelial cells is required, and the presence of one cell with fluorescence constitutes a positive test. ImmunoCyt is US FDA-approved for use in conjunction with urine cytology and cystoscopy.</p><p>The reported sensitivity and specificity of the test usually vary between 70 and 80 percent and 60 and 70 percent, respectively [<a href="#rid31">31</a>]. In a meta-analysis, ImmunoCyt showed the highest sensitivity in evaluating symptoms and for surveillance [<a href="#rid5">5</a>]. Many studies have reported that adding ImmunoCyt to a standard urine cytology protocol increases sensitivity to around 86 to 90 percent without significantly decreasing specificity [<a href="#rid50">50-56</a>]. In one study that included over 1180 patients who presented with painless hematuria, the use of immunocytology was found to be a better predictor for bladder cancer than the use of routine cytology [<a href="#rid57">57</a>].</p><p>Difficulties associated with the ImmunoCyt assay include a steep learning curve, substantial interobserver variability, the need for constant quality control, and a relatively high rate of test failure due to inadequate specimen cellularity.</p><p class="headingAnchor" id="H16"><span class="h2">DD23 monoclonal antibody</span><span class="headingEndMark"> — </span>DD23 is a monoclonal antibody that detects a protein dimer expressed on bladder tumor cells. It has been integrated into an immunocytochemical assay for exfoliated tumor cells in the urine.</p><p>The assay sensitivity increases when DD23 is used in combination with cytology (78 to 85 percent). The marker has a reasonable sensitivity to detect both low-grade (range 55 to 72 percent) and high-grade (range 76 to 87 percent) tumors.</p><p class="headingAnchor" id="H17"><span class="h2">Lewis X antigen</span><span class="headingEndMark"> — </span>Glycoproteins are important cellular structural proteins that contain covalently linked oligosaccharide chains. Glycoproteins also act as antigens.</p><p>The most commonly studied glycoprotein antigen in bladder cancer is the blood group antigen, stage-specific embryonic antigen 1 (SSEA-1) or the sialyl Lewis X (commonly referred to as Lewis X). The Lewis X determinant is a tumor-associated antigen in the urothelium and is visualized in exfoliated tumor cells in the urine by an immunocytochemical assay [<a href="#rid58">58</a>]. At least 100 cells are required for evaluation, and slides showing more than 5 percent positive cells for Lewis X are considered positive.</p><p>Immunocytology for Lewis X antigen on two consecutive voided samples instead of one may increase the sensitivity of the test by almost 15 percent points [<a href="#rid59">59,60</a>]. The sensitivity also increases with increasing stage and grade of the tumor [<a href="#rid61">61</a>]. More reports have indicated that the test has higher sensitivity than BTA-stat, NMP22, and UroVysion approaches, although the specificity was the lowest (range 33 to 37 percent) [<a href="#rid62">62,63</a>]. However, the expression of Lewis X antigen by benign umbrella cells of the urothelium shed in the urine may interfere with the assay [<a href="#rid58">58,64</a>].</p><p class="headingAnchor" id="H29199959"><span class="h2">MicroRNA markers</span><span class="headingEndMark"> — </span>MicroRNAs (miRNAs) are a group of short non-coding RNAs that play an important role in gene silencing, acting on the posttranscriptional level.</p><p>Several miRNAs have been studied. For bladder cancer, miRNA-126, miRNA-200c, miRNA-143, and miRNA-222 showed promising results. The levels of miRNAs after centrifugation can be monitored separately in the urine sediment and supernatant. Two meta-analyses reported a sensitivity for the detection of bladder cancer of 0.75 to 0.85 and a specificity of 0.75 to 0.85 [<a href="#rid65">65,66</a>]. RNA signatures have been linked to aggressive tumor biology [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H4155779946"><span class="h2">Gene expression panels</span><span class="headingEndMark"> — </span>Several groups have examined the value of multigene panels in detection of bladder cancer from urine samples [<a href="#rid68">68,69</a>]. Of note, these tests have yet to undergo large-scale independent validation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cxbladder test</strong> – The Cxbladder test quantifies five mRNA biomarkers found in urine: four biomarkers (insulin-like growth factor-binding protein 5 [<em>IGFBP5</em>], homeobox A13 [<em>HOXA13</em>], midkine [<em>MDK</em>],<em> </em>and cyclin-dependent kinase 1 [<em>CDK1</em>]) associated with growth and propagation of tumor tissue and a fifth biomarker of inflammation (chemokine receptor 2 [<em>CXCR2</em>]) that has been shown to reduce false-positive results by identifying patients with nonmalignant inflammatory conditions [<a href="#rid70">70,71</a>].</p><p></p><p class="bulletIndent1">The test suite includes assays to potentially rule out the presence of bladder cancer in low-risk patients with hematuria (Cxbladder Triage), complement cystoscopy for bladder cancer detection in the presence of hematuria (Cxbladder Detect) [<a href="#rid72">72</a>], and complement cystoscopy for surveillance of recurrent disease (Cxbladder Monitor). The Cxbladder Triage test combines the marker panel with phenotypic characteristics of the patient; this combination had 95 percent sensitivity, compared with 86 percent for the biomarker panel alone [<a href="#rid73">73</a>]. Eighty percent of patients with microhematuria who did not have bladder cancer were correctly triaged out by the test, therefore not requiring a full urological work-up. A comparison of Cxbladder Detect with cytology, NMP22, and UroVysion based on imputation of multiple datasets including 939 subjects showed that the test had a higher sensitivity and signal-to-noise ratio [<a href="#rid74">74</a>]. In a study of 803 patients undergoing surveillance for bladder cancer, Cxbladder Monitor had superior sensitivity and a negative predictive value compared with cytology, NMP22, and UroVysion [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent1">Incorporation of Cxbladder testing results into the clinical evaluation may reduce the number of unnecessary invasive diagnostic procedures in patients with asymptomatic microscopic hematuria, based on a real-world utility analysis [<a href="#rid76">76</a>]. As an example, inclusion of Cxbladder Monitor into a surveillance protocol for 309 patients provided clinical utility by reducing the average number of annual cystoscopies by approximately 39 percent without compromising detection rates [<a href="#rid77">77</a>]. A retrospective pooled analysis from three prospective trials and one observational study reported a 97 percent negative predictive value for Cxbladder compared with 93 percent for cytology; Cxbladder missed 8.5 percent and cytology missed 63 percent of tumors [<a href="#rid78">78</a>]. Cxbladder correctly adjudicated all patients including those with atypical cytology and equivocal cystoscopy when they were diagnosed with bladder cancer based on pathology.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Xpert Bladder Cancer Monitor</strong> – Xpert Bladder Cancer Monitor is another mRNA-based urinary biomarker test developed for bladder cancer surveillance. It quantitatively measures levels of five mRNAs associated with cell proliferation and survival (<em>IGF2</em>); cell growth, division and signal transduction (<em>ANXA10</em>, <em>ABL1</em>); epigenetic dysregulation (<em>UPK1B</em>); and response to neuroendocrine stress, immunity, and inflammation (<em>CRH</em>) from a voided urine sample.</p><p></p><p class="bulletIndent1">Initial studies reported a diagnostic accuracy of 87 percent, with overall sensitivity of 73 percent. Specificity was 90 and 77 percent in the hematuria and surveillance populations, respectively [<a href="#rid79">79</a>]. A prospective validation study confirmed overall sensitivity and negative predictive value of 74 and 93 percent, respectively; the corresponding parameters for patients with high-grade tumors on surveillance were 83 and 98 percent, respectively [<a href="#rid80">80</a>]. The specificity was 80 percent overall and 95 percent in patients without history of bladder cancer.</p><p></p><p class="bulletIndent1">For patients undergoing surveillance, data are mixed for the accuracy of this test compared to cytology. One study in patients with non-muscle invasive bladder cancer noted higher overall sensitivity and negative predictive value for Xpert Bladder Cancer Monitor compared to bladder washing cytology (84 versus 33 percent; 93 versus 76 percent, respectively), along with comparable specificity (91 versus 94 percent) [<a href="#rid81">81</a>]. However, in another prospective marker-comparison study of 230 patients undergoing bladder cancer surveillance, compared with cytology, Xpert Bladder Cancer Monitor had better sensitivity (46.2 versus 11.5 percent) but worse specificity (77 versus 97.2 percent) [<a href="#rid82">82</a>].</p><p></p><p class="headingAnchor" id="H2776275896"><span class="h2">Epigenetic markers</span><span class="headingEndMark"> — </span>Alterations in DNA methylation status have been noted in several malignancies, including bladder cancer. Bladder EpiCheck is a urine-based assay developed for the surveillance of non-muscle invasive bladder cancer as an adjunct to cystoscopy [<a href="#rid83">83</a>]. It is based on the assessment of 15 genomic loci that are associated with a high prevalence of DNA methylation in bladder cancer cells.</p><p>Across several large studies, the assay has reported sensitivity of 62 to 68 percent and specificity of 82 to 88 percent for detecting bladder cancer recurrence [<a href="#rid83">83-85</a>]. When low-grade Ta recurrences were excluded, test sensitivity improved (up to 83 to 92 percent) [<a href="#rid83">83,84</a>]. A head-to-head study of the Xpert Bladder Cancer Monitor and Bladder EpiCheck tests demonstrated comparable performance metrics, although specificity was still inferior to traditional urine cytology [<a href="#rid85">85</a>].</p><p class="headingAnchor" id="H19"><span class="h2">Automated image cytometry</span><span class="headingEndMark"> — </span>Abnormalities in DNA ploidy and nuclear shape are characteristic of tumor cells. While cytologists rely on identification of these changes in urine specimens, automated image analysis identifies changes on a more objective basis.</p><p>Artificial intelligence and neural network technology have been used to develop a digitized cell image diagnosis system that identifies potentially abnormal cells in bladder washings by algorithmic analysis and displays them to a cytopathologist for final evaluation [<a href="#rid86">86</a>].</p><p>One system (Quanticyt) employs image analysis to identify DNA ploidy abnormalities and nuclear morphometry, and scores samples as low, intermediate, or high risk [<a href="#rid87">87</a>]. A study has shown that predictions of a cystoscopic lesion by routine cytology and by Quanticyt were similar, and the latter was superior to predict tumor recurrence after a normal cystoscopy [<a href="#rid88">88</a>]. Use of Quanticyt to analyze consecutive bladder washes may increase the detection rate of invasive disease in samples that are labeled high risk [<a href="#rid89">89</a>].</p><p>In one pilot study, the neural-network-based diagnosis system showed 92 percent sensitivity in diagnosing histologically confirmed tumors, as opposed to 69 percent for Quanticyt and 50 percent for routine cytology [<a href="#rid86">86</a>]. While the major advantage of these cytometric analyses is label-free quantification that closely mimics the routine cytology procedure, a drawback is the need for a bladder wash sample instead of voided urine.</p><p class="headingAnchor" id="H2739192241"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/122007.html" rel="external">"Society guideline links: Bladder cancer"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urine biomarkers</strong> – Improved diagnostic techniques are required both for individuals in whom there is a high suspicion of bladder cancer and for those under surveillance after treatment for early non-muscle invasive bladder cancer. (See <a class="local">'Potential applications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Numerous urine biomarkers have been developed or are being studied  (<a class="graphic graphic_table graphicRef70530" href="/d/graphic/70530.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef59814" href="/d/graphic/59814.html" rel="external">table 2</a>). These approaches have demonstrated a substantially higher sensitivity than urine cytology but a significantly lower specificity. (See <a class="local">'Urine biomarkers'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Additional studies are required to determine the optimal way to integrate these newer techniques into patient management.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Despite the promise of urine biomarkers, cystoscopy remains the procedure of choice both for initial diagnosis and for surveillance in previously treated patients. (See  <a class="medical medical_review" href="/d/html/2977.html" rel="external">"Screening for bladder cancer"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Laucirica R, Bentz JS, Souers RJ, et al. Do liquid-based preparations of urinary cytology perform differently than classically prepared cases? Observations from the College of American Pathologists Interlaboratory Comparison Program in Nongynecologic Cytology. Arch Pathol Lab Med 2010; 134:19.</a></li><li><a class="nounderline abstract_t">Birkhahn M, Mitra AP, Williams AJ, et al. A novel precision-engineered microfiltration device for capture and characterisation of bladder cancer cells in urine. Eur J Cancer 2013; 49:3159.</a></li><li><a class="nounderline abstract_t">Mitra AP, Cote RJ. Molecular screening for bladder cancer: progress and potential. Nat Rev Urol 2010; 7:11.</a></li><li><a class="nounderline abstract_t">Tilki D, Burger M, Dalbagni G, et al. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol 2011; 60:484.</a></li><li><a class="nounderline abstract_t">Chou R, Gore JL, Buckley D, et al. Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-analysis. Ann Intern Med 2015; 163:922.</a></li><li><a class="nounderline abstract_t">Abd El Gawad IA, Moussa HS, Nasr MI, et al. Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer. J Egypt Natl Canc Inst 2005; 17:193.</a></li><li><a class="nounderline abstract_t">Raitanen MP, FinnBladder Group. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies. World J Urol 2008; 26:45.</a></li><li><a class="nounderline abstract_t">Guo A, Wang X, Gao L, et al. Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: A meta-analysis. Can Urol Assoc J 2014; 8:E347.</a></li><li><a class="nounderline abstract_t">Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003; 61:109.</a></li><li><a class="nounderline abstract_t">Eissa S, Swellam M, Sadek M, et al. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. J Urol 2002; 168:465.</a></li><li><a class="nounderline abstract_t">Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005; 293:810.</a></li><li><a class="nounderline abstract_t">Grossman HB, Soloway M, Messing E, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 2006; 295:299.</a></li><li><a class="nounderline abstract_t">Shariat SF, Savage C, Chromecki TF, et al. Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis. Cancer 2011; 117:2892.</a></li><li><a class="nounderline abstract_t">Yafi FA, Brimo F, Steinberg J, et al. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol 2015; 33:66.e25.</a></li><li><a class="nounderline abstract_t">Attallah AM, Sakr HA, Ismail H, et al. An office-based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer. BJU Int 2005; 96:334.</a></li><li><a class="nounderline abstract_t">Getzenberg RH, Konety BR, Oeler TA, et al. Bladder cancer-associated nuclear matrix proteins. Cancer Res 1996; 56:1690.</a></li><li><a class="nounderline abstract_t">Myers-Irvin JM, Landsittel D, Getzenberg RH. Use of the novel marker BLCA-1 for the detection of bladder cancer. J Urol 2005; 174:64.</a></li><li><a class="nounderline abstract_t">Konety BR, Nguyen TS, Dhir R, et al. Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res 2000; 6:2618.</a></li><li><a class="nounderline abstract_t">Black PC, Brown GA, Dinney CP. Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J Clin Oncol 2006; 24:5528.</a></li><li><a class="nounderline abstract_t">Yoder BJ, Skacel M, Hedgepeth R, et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007; 127:295.</a></li><li><a class="nounderline abstract_t">Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol 2008; 26:646.</a></li><li><a class="nounderline abstract_t">Lokeshwar VB, Habuchi T, Grossman HB, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005; 66:35.</a></li><li><a class="nounderline abstract_t">Schlomer BJ, Ho R, Sagalowsky A, et al. Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 2010; 183:62.</a></li><li><a class="nounderline abstract_t">Kipp BR, Karnes RJ, Brankley SM, et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 2005; 173:401.</a></li><li><a class="nounderline abstract_t">Whitson J, Berry A, Carroll P, Konety B. A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy. BJU Int 2009; 104:336.</a></li><li><a class="nounderline abstract_t">Savic S, Zlobec I, Thalmann GN, et al. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy. Int J Cancer 2009; 124:2899.</a></li><li><a class="nounderline abstract_t">Halling KC, King W, Sokolova IA, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000; 164:1768.</a></li><li><a class="nounderline abstract_t">Bubendorf L, Grilli B, Sauter G, et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001; 116:79.</a></li><li><a class="nounderline abstract_t">Sarosdy MF, Schellhammer P, Bokinsky G, et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002; 168:1950.</a></li><li><a class="nounderline abstract_t">Skacel M, Fahmy M, Brainard JA, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003; 169:2101.</a></li><li><a class="nounderline abstract_t">Lokeshwar VB, Selzer MG. Urinary bladder tumor markers. Urol Oncol 2006; 24:528.</a></li><li><a class="nounderline abstract_t">Lokeshwar VB, Obek C, Pham HT, et al. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol 2000; 163:348.</a></li><li><a class="nounderline abstract_t">Passerotti CC, Srougi M, Bomfim AC, et al. Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma. Urol Oncol 2011; 29:710.</a></li><li><a class="nounderline abstract_t">Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266:2011.</a></li><li><a class="nounderline abstract_t">Mucciardi G, Gali' A, Barresi V, et al. Telomere instability in papillary bladder urothelial carcinomas: Comparison with grading and risk of recurrence. Indian J Urol 2014; 30:245.</a></li><li><a class="nounderline abstract_t">Birkhahn M, Mitra AP, Cote RJ. Molecular markers for bladder cancer: the road to a multimarker approach. Expert Rev Anticancer Ther 2007; 7:1717.</a></li><li><a class="nounderline abstract_t">Shariat SF, Casella R, Khoddami SM, et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 2004; 171:626.</a></li><li><a class="nounderline abstract_t">Margulis V, Lotan Y, Shariat SF. Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol 2008; 26:59.</a></li><li><a class="nounderline abstract_t">Smith SD, Wheeler MA, Plescia J, et al. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001; 285:324.</a></li><li><a class="nounderline abstract_t">Moussa O, Abol-Enein H, Bissada NK, et al. Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer. J Urol 2006; 175:2312.</a></li><li><a class="nounderline abstract_t">Kenney DM, Geschwindt RD, Kary MR, et al. Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative rt-PCR of urinary survivin. Tumour Biol 2007; 28:57.</a></li><li><a class="nounderline abstract_t">Pu XY, Wang ZP, Chen YR, et al. The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine. J Cancer Res Clin Oncol 2008; 134:659.</a></li><li><a class="nounderline abstract_t">Ku JH, Godoy G, Amiel GE, Lerner SP. Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review. BJU Int 2012; 110:630.</a></li><li><a class="nounderline abstract_t">Tsihlias J, Grossman HB. The utility of fibrin/fibrinogen degradation products in superficial bladder cancer. Urol Clin North Am 2000; 27:39.</a></li><li><a class="nounderline abstract_t">Berger AP, Parson W, Stenzl A, et al. Microsatellite alterations in human bladder cancer: detection of tumor cells in urine sediment and tumor tissue. Eur Urol 2002; 41:532.</a></li><li><a class="nounderline abstract_t">Rouprêt M, Hupertan V, Yates DR, et al. A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. BJU Int 2008; 101:1448.</a></li><li><a class="nounderline abstract_t">van der Aa MN, Zwarthoff EC, Steyerberg EW, et al. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]). Eur Urol 2009; 55:659.</a></li><li><a class="nounderline abstract_t">de Bekker-Grob EW, van der Aa MN, Zwarthoff EC, et al. Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative? BJU Int 2009; 104:41.</a></li><li><a class="nounderline abstract_t">Christensen M, Wolf H, Orntoft TF. Microsatellite alterations in urinary sediments from patients with cystitis and bladder cancer. Int J Cancer 2000; 85:614.</a></li><li><a class="nounderline abstract_t">Têtu B, Tiguert R, Harel F, Fradet Y. ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod Pathol 2005; 18:83.</a></li><li><a class="nounderline abstract_t">Mian C, Pycha A, Wiener H, et al. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol 1999; 161:1486.</a></li><li><a class="nounderline abstract_t">Lodde M, Mian C, Wiener H, et al. Detection of upper urinary tract transitional cell carcinoma with ImmunoCyt: a preliminary report. Urology 2001; 58:362.</a></li><li><a class="nounderline abstract_t">Pfister C, Chautard D, Devonec M, et al. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol 2003; 169:921.</a></li><li><a class="nounderline abstract_t">Mian C, Lodde M, Comploj E, et al. The value of the ImmunoCyt/uCyt+ test in the detection and follow-up of carcinoma in situ of the urinary bladder. Anticancer Res 2005; 25:3641.</a></li><li><a class="nounderline abstract_t">Mian C, Maier K, Comploj E, et al. uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses. Cancer 2006; 108:60.</a></li><li><a class="nounderline abstract_t">Lodde M, Mian C, Comploj E, et al. uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma. Urology 2006; 67:950.</a></li><li><a class="nounderline abstract_t">Cha EK, Tirsar LA, Schwentner C, et al. Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study. Eur Urol 2012; 61:185.</a></li><li><a class="nounderline abstract_t">Sheinfeld J, Reuter VE, Melamed MR, et al. Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation. J Urol 1990; 143:285.</a></li><li><a class="nounderline abstract_t">Golijanin D, Sherman Y, Shapiro A, Pode D. Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine. Urology 1995; 46:173.</a></li><li><a class="nounderline abstract_t">Pode D, Golijanin D, Sherman Y, et al. Immunostaining of Lewis X in cells from voided urine, cytopathology and ultrasound for noninvasive detection of bladder tumors. J Urol 1998; 159:389.</a></li><li><a class="nounderline abstract_t">Shirahama T, Ikoma M, Muramatsu T, Ohi Y. Expression of SSEA-1 carbohydrate antigen correlates with stage, grade and metastatic potential of transitional cell carcinoma of the bladder. J Urol 1992; 148:1319.</a></li><li><a class="nounderline abstract_t">Friedrich MG, Hellstern A, Hautmann SH, et al. Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests. J Urol 2002; 168:470.</a></li><li><a class="nounderline abstract_t">Toma MI, Friedrich MG, Hautmann SH, et al. Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. World J Urol 2004; 22:145.</a></li><li><a class="nounderline abstract_t">Loy TS, Alexander CJ, Calaluce RD. Lewis X antigen immunostaining in the diagnosis of transitional cell carcinoma. Mod Pathol 1995; 8:587.</a></li><li><a class="nounderline abstract_t">Cheng Y, Deng X, Yang X, et al. Urine microRNAs as biomarkers for bladder cancer: a diagnostic meta-analysis. Onco Targets Ther 2015; 8:2089.</a></li><li><a class="nounderline abstract_t">Chen L, Cui Z, Liu Y, et al. MicroRNAs as Biomarkers for the Diagnostics of Bladder Cancer: a Meta-Analysis. Clin Lab 2015; 61:1101.</a></li><li><a class="nounderline abstract_t">Pignot G, Cizeron-Clairac G, Vacher S, et al. microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer 2013; 132:2479.</a></li><li><a class="nounderline abstract_t">de Jong JJ, Pijpers OM, van Kessel KEM, et al. A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines. Eur Urol Oncol 2023; 6:183.</a></li><li><a class="nounderline abstract_t">van Kessel KE, Beukers W, Lurkin I, et al. Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy. J Urol 2017; 197:590.</a></li><li><a class="nounderline abstract_t">Holyoake A, O'Sullivan P, Pollock R, et al. Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder. Clin Cancer Res 2008; 14:742.</a></li><li><a class="nounderline abstract_t">O'Sullivan P, Sharples K, Dalphin M, et al. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol 2012; 188:741.</a></li><li><a class="nounderline abstract_t">Lotan Y, Raman JD, Konety B, et al. Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification. J Urol 2023; 209:762.</a></li><li><a class="nounderline abstract_t">Kavalieris L, O'Sullivan PJ, Suttie JM, et al. A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma. BMC Urol 2015; 15:23.</a></li><li><a class="nounderline abstract_t">Breen V, Kasabov N, Kamat AM, et al. A holistic comparative analysis of diagnostic tests for urothelial carcinoma: a study of Cxbladder Detect, UroVysion® FISH, NMP22® and cytology based on imputation of multiple datasets. BMC Med Res Methodol 2015; 15:45.</a></li><li><a class="nounderline abstract_t">Lotan Y, OʼSullivan P, Raman JD, et al. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urol Oncol 2017; 35:531.e15.</a></li><li><a class="nounderline abstract_t">Lough T, Luo Q, Luxmanan C, et al. Clinical utility of a non-invasive urine test for risk assessing patients with no obvious benign cause of hematuria: a physician-patient real world data analysis. BMC Urol 2018; 18:18.</a></li><li><a class="nounderline abstract_t">Koya M, Osborne S, Chemaslé C, et al. An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer. BMC Urol 2020; 20:12.</a></li><li><a class="nounderline abstract_t">Konety B, Shore N, Kader AK, et al. Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy. Eur Urol 2019; 76:238.</a></li><li><a class="nounderline abstract_t">Wallace E, Higuchi R, Satya M, et al. Development of a 90-Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection. J Urol 2018; 199:655.</a></li><li><a class="nounderline abstract_t">Valenberg FJPV, Hiar AM, Wallace E, et al. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. Eur Urol 2019; 75:853.</a></li><li><a class="nounderline abstract_t">Pichler R, Fritz J, Tulchiner G, et al. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance. BJU Int 2018; 121:29.</a></li><li><a class="nounderline abstract_t">D Elia C, Pycha A, Folchini DM, et al. Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer. J Clin Pathol 2019; 72:140.</a></li><li><a class="nounderline abstract_t">Witjes JA, Morote J, Cornel EB, et al. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial. Eur Urol Oncol 2018; 1:307.</a></li><li><a class="nounderline abstract_t">Trenti E, D'Elia C, Mian C, et al. Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer. Cancer Cytopathol 2019; 127:465.</a></li><li><a class="nounderline abstract_t">Trenti E, Pycha S, Mian C, et al. Comparison of 2 new real-time polymerase chain reaction-based urinary markers in the follow-up of patients with non-muscle-invasive bladder cancer. Cancer Cytopathol 2020; 128:341.</a></li><li><a class="nounderline abstract_t">Vriesema JL, van der Poel HG, Debruyne FM, et al. Neural network-based digitized cell image diagnosis of bladder wash cytology. Diagn Cytopathol 2000; 23:171.</a></li><li><a class="nounderline abstract_t">van der Poel HG, Witjes JA, van Stratum P, et al. Quanticyt: karyometric analysis of bladder washing for patients with superficial bladder cancer. Urology 1996; 48:357.</a></li><li><a class="nounderline abstract_t">van der Poel HG, Boon ME, van Stratum P, et al. Conventional bladder wash cytology performed by four experts versus quantitative image analysis. Mod Pathol 1997; 10:976.</a></li><li><a class="nounderline abstract_t">van der Poel HG, van Rhijn BW, Peelen P, et al. Consecutive quantitative cytology in bladder cancer. Urology 2000; 56:584.</a></li></ol></div><div id="topicVersionRevision">Topic 2968 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20073599" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Do liquid-based preparations of urinary cytology perform differently than classically prepared cases? Observations from the College of American Pathologists Interlaboratory Comparison Program in Nongynecologic Cytology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23849827" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A novel precision-engineered microfiltration device for capture and characterisation of bladder cancer cells in urine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20062071" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Molecular screening for bladder cancer: progress and potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21684071" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Urine markers for detection and surveillance of non-muscle-invasive bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26501851" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16799657" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18180926" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24940462" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12559279" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12131289" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15713770" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Detection of bladder cancer using a point-of-care proteomic assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16418465" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21692050" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25037483" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16042726" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : An office-based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8603421" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Bladder cancer-associated nuclear matrix proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15947579" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Use of the novel marker BLCA-1 for the detection of bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10914702" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17158538" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17210520" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18367109" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16399415" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19913822" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15643180" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19220253" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19230026" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11025767" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11447756" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12394683" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12771727" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17138134" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Urinary bladder tumor markers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10604388" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19962919" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7605428" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Specific association of human telomerase activity with immortal cells and cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25097306" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Telomere instability in papillary bladder urothelial carcinomas: Comparison with grading and risk of recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18062746" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Molecular markers for bladder cancer: the road to a multimarker approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14713774" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17962949" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Survivin: a promising biomarker for detection and prognosis of bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11176843" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Urine detection of survivin and diagnosis of bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16697865" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17259754" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative rt-PCR of urinary survivin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18026991" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22353238" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10696243" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The utility of fibrin/fibrinogen degradation products in superficial bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12074795" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Microsatellite alterations in human bladder cancer: detection of tumor cells in urine sediment and tumor tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18325051" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18501499" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19500328" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10699938" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Microsatellite alterations in urinary sediments from patients with cystitis and bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15389253" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10210378" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11549481" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Detection of upper urinary tract transitional cell carcinoma with ImmunoCyt: a preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12576813" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16101194" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The value of the ImmunoCyt/uCyt+ test in the detection and follow-up of carcinoma in situ of the urinary bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16411183" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16698355" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21924544" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2405185" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7624989" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9649245" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Immunostaining of Lewis X in cells from voided urine, cytopathology and ultrasound for noninvasive detection of bladder tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1357195" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Expression of SSEA-1 carbohydrate antigen correlates with stage, grade and metastatic potential of transitional cell carcinoma of the bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12131290" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14991320" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8532688" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Lewis X antigen immunostaining in the diagnosis of transitional cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26316777" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Urine microRNAs as biomarkers for bladder cancer: a diagnostic meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26427157" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : MicroRNAs as Biomarkers for the Diagnostics of Bladder Cancer: a Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23169479" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36089502" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27746284" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18245534" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22818138" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36583640" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25888331" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25962444" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : A holistic comparative analysis of diagnostic tests for urothelial carcinoma: a study of Cxbladder Detect, UroVysion®FISH, NMP22®and cytology based on imputation of multiple datasets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28366272" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29523118" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Clinical utility of a non-invasive urine test for risk assessing patients with no obvious benign cause of hematuria: a physician-patient real world data analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32046687" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31103391" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29061538" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Development of a 90-Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30553612" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28941000" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30355587" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31100252" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Performance of the Bladder EpiCheck™Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31154670" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31977131" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Comparison of 2 new real-time polymerase chain reaction-based urinary markers in the follow-up of patients with non-muscle-invasive bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10945904" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Neural network-based digitized cell image diagnosis of bladder wash cytology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8804485" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Quanticyt: karyometric analysis of bladder washing for patients with superficial bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9346176" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Conventional bladder wash cytology performed by four experts versus quantitative image analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11018610" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Consecutive quantitative cytology in bladder cancer.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
